ALE.F02

Phase 2Small molecule

ALE.F02 is one of 5 small molecule programs targeting Glomerulonephritis Rapidly Progressive. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Glomerulonephritis Rapidly ProgressiveRecruiting

Glomerulonephritis Rapidly ProgressivePhase 2

Recruiting

Competition

Competitive Landscape

4 competitors in Glomerulonephritis Rapidly Progressive

#DrugCompanyPhaseTrials

Rituxan

Roche

Phase 2

1 2

Glucocorticoid

AbbVie

Phase 2

1 3

Cyclophosphamid

EEssen Biotech

Phase 2

1 4

Immunosuppressive Agents

MMedeor Therapeutics, Inc.

Phase 2

1 5

ALE.F02

AAlentis Therapeutics AG

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Recruiting

Glomerulonephritis Rapidly Progressive

NCT06047171

Clinical

Trials by Indication[1]

Cirrhosis1 trial

A Clinical Trial of ALE.F02 in Patients With Advanced Liver Fibrosis and/or With Mild Cirrhosis

Completed·AAlentis Therapeutics AG·Phase 1·NCT05939947·41 enrolled

Glomerulonephritis Rapidly Progressive1 trial

A Randomized, Double-Blind, Placebo-Controlled Study of Intravenously Administered ALE.F02 to Evaluate the Safety, Tolerability, Pharmacokinetics, and Renal Sparing in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis With Rapidly Progressive Glomerulonephritis

Recruiting·AAlentis Therapeutics AG·Phase 2·NCT06047171·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for ALE.F02. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — ALE.F02 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for ALE.F02. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Alentis Therapeutics AG company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: AAlentis Therapeutics AG

ALE.F02

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Cirrhosis1 trial

Glomerulonephritis Rapidly Progressive1 trial

References

Drug Info

Quick Facts

Related News